

NEWSFLASH



University of
Nottingham
UK | CHINA | MALAYSIA



CerebroVascular Disease-Cognition phase-2 trial in non-lacunar ischaemic stroke with cerebral small vessel disease

CVD-Cog has secured funding from the Alzheimer's Society.

We are now in the final stages of preparation, with ethics and regulatory submissions underway and on track for approval.

We aim to start site set-up in October 2025 and open recruitment in December 2025. Thank you for all expressions of interest so far - we look forward to working with you as we move closer to approval.

Trial Summary

PURPOSE: The purpose of CVD-Cog is to investigate whether isosorbide mononitrate and/or cilostazol are effective in treating cerebral small vessel disease (cSVD) in patients who have had a non-lacunar ischaemic stroke or TIA.

DESIGN: Prospective randomised open-label blinded-endpoint partial-factorial trial.

PARTICIPANTS: 400 participants will be recruited from 25 sites. Participants must be 7 days from diagnosis with a non-lacunar ischaemic stroke or TIA and have cSVD on their CT and/or MR brain scan.

INTERVENTION: Participants not taking an oral anti-coagulant will be assigned at random to one of four treatment groups:

1. Isosorbide mononitrate only.
2. Cilostazol only.
3. Both cilostazol and isosorbide mononitrate.
4. Neither cilostazol nor isosorbide mononitrate.

Participants on an oral anti-coagulant will be randomised to isosorbide mononitrate or no isosorbide mononitrate.

FOLLOW UP: Participants will be treated and followed for 6 months. The trial is funded for 3 years.

Follow our progress on @CVDCog

If you have any questions, please get in touch:



CVDCog@nottingham.ac.uk